NovoCure (NVCR) to Release Quarterly Earnings on Thursday

NovoCure (NASDAQ:NVCR) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect NovoCure to post earnings of ($0.40) per share and revenue of $174.3980 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

NovoCure Trading Up 2.4%

Shares of NovoCure stock opened at $11.40 on Thursday. The company has a fifty day simple moving average of $12.79 and a 200-day simple moving average of $12.60. NovoCure has a 12-month low of $9.82 and a 12-month high of $22.30. The company has a current ratio of 1.55, a quick ratio of 1.50 and a debt-to-equity ratio of 0.57. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -7.08 and a beta of 0.73.

Institutional Trading of NovoCure

Several hedge funds have recently made changes to their positions in NVCR. Alliancebernstein L.P. increased its stake in shares of NovoCure by 0.8% during the third quarter. Alliancebernstein L.P. now owns 137,106 shares of the medical equipment provider’s stock worth $1,771,000 after acquiring an additional 1,076 shares during the period. Royal Bank of Canada boosted its holdings in NovoCure by 14.9% in the 4th quarter. Royal Bank of Canada now owns 12,830 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 1,667 shares in the last quarter. LPL Financial LLC increased its position in NovoCure by 15.1% during the 4th quarter. LPL Financial LLC now owns 16,380 shares of the medical equipment provider’s stock worth $212,000 after purchasing an additional 2,153 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of NovoCure by 3.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider’s stock worth $1,336,000 after buying an additional 2,502 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of NovoCure in the 4th quarter valued at approximately $33,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Wedbush reaffirmed a “neutral” rating and set a $18.00 price objective on shares of NovoCure in a report on Thursday, January 15th. JPMorgan Chase & Co. dropped their price target on NovoCure from $25.00 to $23.00 and set a “neutral” rating on the stock in a research note on Monday, October 27th. HC Wainwright boosted their price objective on NovoCure from $39.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. Finally, Evercore set a $20.00 target price on shares of NovoCure in a report on Monday, January 5th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $26.64.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.